Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XAKNUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
XAKNSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XAKNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XAANUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XAANUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XAANUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XAANUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XAANUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
XAANUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
XAANSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-19568.4US
XAANSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.3.8NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BA.2.3.8NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BA.2.3.8NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.3.8NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.3.8NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.2.3.8NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
BA.2.3.8NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.2.3.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.569NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-15625.1US
B.1.569NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.1.569NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.569NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.569NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.569NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.569NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.569NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.524NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.524NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.1.524NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.524NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.524NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.524NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.524NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.524NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
A.23NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
A.23NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
A.23NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
A.23NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
A.23NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
A.23NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
A.23NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
A.23NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.596.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.596.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.1.596.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.596.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.596.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.596.1NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.596.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used